Accumulating evidence has indicated that dysregulation of m6A modification, m6A methyltransferases, demethylases, and RNA‐binding proteins may be involved in diabetes, infertility, cancers (Shen et al., 2015; Sibbritt, Patel, & Preiss, 2013; Sun, Wu, & Ming, 2019; Yang et al., 2016), supporting the hypothesis that m6A and the methylation modifier including m6A methyltransferases, demethylases, and RNA‐binding proteins have potential to be new prognostic biomarkers, and novel therapy targets of diseases (Zhao et al., 2018). This evidence concerns the gene MBD2 and cancer.